Top

Published in:

01-05-2012 | Original article

Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy

Authors: M. Geier, S.T. Astner, M.N. Duma, V. Jacob, C. Nieder, J. Putzhammer, C. Winkler, M. Molls, Prof. Dr. H. Geinitz

Published in: Strahlentherapie und Onkologie | Issue 5/2012

Abstract

Purpose

The goal of this work was to assess the feasibility of moderately hypofractionated simultaneous integrated-boost intensity-modulated radiotherapy (SIB-IMRT) with helical tomotherapy in patients with localized prostate cancer regarding acute side effects and dose–volume histogram data (DVH data).

Methods

Acute side effects and DVH data were evaluated of the first 40 intermediate risk prostate cancer patients treated with a definitive daily image-guided SIB-IMRT protocol via helical tomotherapy in our department. The planning target volume including the prostate and the base of the seminal vesicles with safety margins was treated with 70 Gy in 35 fractions. The boost volume containing the prostate and 3 mm safety margins (5 mm craniocaudal) was treated as SIB to a total dose of 76 Gy (2.17 Gy per fraction). Planning constraints for the anterior rectal wall were set in order not to exceed the dose of 76 Gy prescribed to the boost volume. Acute toxicity was evaluated prospectively using a modified CTCAE (Common Terminology Criteria for Adverse Events) score.

Results

SIB-IMRT allowed good rectal sparing, although the full boost dose was permitted to the anterior rectal wall. Median rectum dose was 38 Gy in all patients and the median volumes receiving at least 65 Gy (V65), 70 Gy (V70), and 75 Gy (V75) were 13.5%, 9%, and 3%, respectively. No grade 4 toxicity was observed. Acute grade 3 toxicity was observed in 20% of patients involving nocturia only. Grade 2 acute intestinal and urological side effects occurred in 25% and 57.5%, respectively. No correlation was found between acute toxicity and the DVH data.

Conclusion

This institutional SIB-IMRT protocol using daily image guidance as a precondition for smaller safety margins allows dose escalation to the prostate without increasing acute toxicity.

Brenner DJ (2003) Hypofractionation for prostate cancer radiotherapy – what are the issues? Int J Radiat Oncol Biol Phys 57:912–914PubMedCrossRef

De Meerleer G, Vakaet L, Meersschout S et al (2004) Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60:777–787CrossRef

Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8:475–487PubMedCrossRef

Di Muzio N, Fiorino C, Cozzarini C et al (2009) Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 74:392–398CrossRef

Dolezel M, Odrazka K, Vaculikova M et al (2010) Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol 186:197–202PubMedCrossRef

Fiorino C, Di Muzio N, Broggi S et al (2008) Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. Int J Radiat Oncol Biol Phys 71:611–617PubMedCrossRef

Fowler JF, Ritter MA, Chappell RJ, Brenner DJ (2003) What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 56:1093–1104PubMedCrossRef

Geinitz H, Thamm R, Keller M et al (2011) Longitudinal study of intestinal symptoms and fecal continence in patients with conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 79:1373–1380PubMedCrossRef

Ghadjar P, Gwerder N, Manser P et al (2010) High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer. Strahlenther Onkol 186:687–692PubMedCrossRef

10.

Goldner G, Dimopoulos J, Kirisits C, Potter R (2009) Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy. Strahlenther Onkol 185:438–445PubMedCrossRef

11.

Guckenberger M, Flentje M (2007) Intensity-modulated radiotherapy (IMRT) of localized prostate cancer: a review and future perspectives. Strahlenther Onkol 183:57–62PubMedCrossRef

12.

Guckenberger M, Ok S, Polat B et al (2010) Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer. Strahlenther Onkol 186:535–543PubMedCrossRef

13.

Hentschel B, Oehler W, Strauss D et al (2011) Definition of the CTV prostate in CT and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer. Strahlenther Onkol 187:183–190PubMedCrossRef

14.

Junius S, Haustermans K, Bussels B et al (2007) Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. Radiat Oncol 2:29PubMedCrossRef

15.

Kassim I, Dirkx ML, Heijmen BJ (2009) Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients. Radiother Oncol 92:62–67PubMedCrossRef

16.

Keiler L, Dobbins D, Kulasekere R, Einstein D (2007) Tomotherapy for prostate adenocarcinoma: a report on acute toxicity. Radiother Oncol 84:171–176PubMedCrossRef

17.

Kotte AN, Hofman P, Lagendijk JJ et al (20007) Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 69:419–425CrossRef

18.

Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74PubMedCrossRef

19.

Kupelian PA, Willoughby TR, Reddy CA et al (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68:1424–1430PubMedCrossRef

20.

Levegrun S, Jackson A, Zelefsky MJ et al (2002) Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 63:11–26PubMedCrossRef

21.

Li XA, Wang JZ, Jursinic PA et al (2005) Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 61:1251–1257PubMedCrossRef

22.

Lordick F, Geinitz H, Theisen J et al (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64:1295–1298PubMedCrossRef

23.

Martin JM, Rosewall T, Bayley A et al (2007) Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 69:1084–1089PubMedCrossRef

24.

Nickers P, Hermesse J, Deneufbourg JM et al (2010) Which alpha/beta ratio and half-time of repair are useful for predicting outcomes in prostate cancer? Radiother Oncol 97(3):462–466PubMedCrossRef

25.

Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996PubMedCrossRef

26.

Pervez N, Small C, MacKenzie M et al (2010) Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 76:57–64PubMedCrossRef

27.

Pollack A, Hanlon AL, Horwitz EM et al (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64:518–526PubMedCrossRef

28.

Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105PubMedCrossRef

29.

Proust-Lima C, Taylor JM, Secher S et al (2011) Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 79:195–201PubMedCrossRef

30.

Roach M 3rd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMedCrossRef

31.

Schwartz DJ, Sengupta S, Hillman DW et al (2007) Prediction of radial distance of extraprostatic extension from pretherapy factors. Int J Radiat Oncol Biol Phys 69:411–418PubMedCrossRef

32.

Singh AK, Guion P, Sears-Crouse N et al (2007) Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol 2:36PubMedCrossRef

33.

Soete G, Arcangeli S, De Meerleer G et al (2006) Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 80:78–81PubMedCrossRef

34.

Wang KK, Vapiwala N, Deville C et al (2011) A study to quantify the effectiveness of daily endorectal balloon for prostate intrafraction motion management. Int J Radiat Oncol Biol Phys (in press)

35.

Zelefsky MJ, Chan H, Hunt M et al (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176:1415–1419PubMedCrossRef

36.

Zelefsky MJ, Fuks Z, Hunt M et al (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111–1116PubMedCrossRef

37.

Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. J Clin Oncol 28:1106–1111PubMedCrossRef

38.

Zucca S, Carau B, Solla I et al (2011) Prostate image-guided radiotherapy by megavolt cone-beam CT. Strahlenther Onkol 187:473–478PubMedCrossRef

Title: Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy
Authors: M. Geier
S.T. Astner
M.N. Duma
V. Jacob
C. Nieder
J. Putzhammer
C. Winkler
M. Molls
Prof. Dr. H. Geinitz
Publication date: 01-05-2012
Publisher: Springer-Verlag
Published in: Strahlentherapie und Onkologie / Issue 5/2012
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0081-8

At a glance: The STEP trials

Springer Medicine

Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2012

Profitieren ältere Patienten von einer Operation zusätzlich zur Strahlentherapie bei der Behandlung der metastatisch bedingten Rückenmarkskompression?

Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer

Neoadjuvante Radiochemotherapie mit 5-FU plus Oxaliplatin beim lokal fortgeschrittenen Rektumkarzinom

Clinical outcome of rectal cancer in patients ≥ 80 years treated in southern France (PACA region) between 2002 and 2005

Welchen Einfluss hat die Lokaltherapie auf das Gesamtüberleben beim Prostatakarzinom?

Risk factors related to interfractional variation in whole pelvic irradiation for locally advanced pelvic malignancies